Cargando…

Diverse Resistant Mechanisms Identified Using Serial Next-Generation Sequencing in a Patient With ALK-Rearranged Metastatic Lung Adenocarcinoma: A Case Report

Both tissue and plasma-based next generation sequencing (NGS) facilitate the identification of actionable oncogene alterations at diagnosis and resistant mechanisms on progression. The value of longitudinal profiling is less established among patients with ALK-rearranged NSCLC, underpinned by concer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saw, Stephanie Pei Li, Lim, Darren Wan-Teck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250920/ https://www.ncbi.nlm.nih.gov/pubmed/37304651 http://dx.doi.org/10.1016/j.jtocrr.2023.100512

Ejemplares similares

Clonally‐related primary ALK rearranged adenocarcinoma and associated metastatic lesions
por: Zhu, You‐cai, et al.
Publicado: (2018)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
por: Dacic, Sanja, et al.
Publicado: (2016)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers
por: Xia, Peiyi, et al.
Publicado: (2021)

ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Generation Sequencing Testing
por: Canterbury, Carleigh R., et al.
Publicado: (2021)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
por: Kwon, Minsuk, et al.
Publicado: (2022)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Decreased Tertiary Lymphoid Structures in Lung Adenocarcinomas with ALK Rearrangements
por: Zou, Yi, et al.
Publicado: (2022)

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
por: Leung, Jackson Ka Chun, et al.
Publicado: (2023)

Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report
por: Yuan, Cai, et al.
Publicado: (2017)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC
por: Kuang, Yukun, et al.
Publicado: (2021)

EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
por: von Buttlar, Xinyu, et al.
Publicado: (2021)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin
por: Moatter, Samar, et al.
Publicado: (2018)

Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangement
por: Kawamoto, Hironori, et al.
Publicado: (2016)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Diffusion-weighted magnetic resonance imaging-directed biopsy of a metastatic bone tumor: Lung adenocarcinoma with ALK rearrangement
por: Hibino, Makoto, et al.
Publicado: (2018)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
por: Incharoen, Pimpin, et al.
Publicado: (2016)

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Marino, Federica Zito, et al.
Publicado: (2015)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer
por: Tan, Chye Ling, et al.
Publicado: (2016)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Zito Marino, Federica, et al.
Publicado: (2015)

Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases
por: Yu, Yongfeng, et al.
Publicado: (2016)

ALK rearrangement in lung adenocarcinoma with concurrent cervix and breast metastases: A case report
por: Chuang, Xin, et al.
Publicado: (2018)

ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
por: Bi, Rui, et al.
Publicado: (2019)

A case of ALK-rearranged lung adenocarcinoma associated with syndrome of inappropriate antidiuretic hormone
por: Miyashita, Yoshihiro, et al.
Publicado: (2020)

ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib
por: Kaiho, Taisuke, et al.
Publicado: (2020)

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
por: Fan, Jun, et al.
Publicado: (2020)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Zhang, Huan, et al.
Publicado: (2021)

ALK ‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
por: Song, Lianxi, et al.
Publicado: (2022)

Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
por: Liao, Juanyan, et al.
Publicado: (2022)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_331opi7c2jqecb9b6eul4m886o